
Agilent Technologies (A) Stock Forecast & Price Target
Agilent Technologies (A) Analyst Ratings
Bulls say
Agilent Technologies is well positioned because its Q3 organic sales growth of 7.3% exceeded expectations, with Life Sciences and Diagnostics up about 10% organically and pharma-related revenue up 9% even excluding CDMO strength. Its outlook is supported by synchronized product cycles across LC, GC, and ICP-MS, plus broad exposure to sticky end markets such as biopharma and chemical/advanced materials, which both showed strong growth and are benefiting from reshoring demand. The company also has a favorable mix of recurring consumables and services, a geographically diverse footprint, and improving margins under IGNITE, suggesting durable revenue momentum and earnings leverage.
Bears say
Agilent Technologies is viewed negatively because its revenue mix is unusually exposed to cyclical end markets, with about 25% from chemical and advanced materials and another 10% from environmental/forensics, making demand vulnerable to macroeconomic deterioration and industrial softness. The company is also more exposed to China than peers, deriving 18% of sales there versus roughly 12% for the peer average, while mixed China conditions and competitive pressure could weigh on growth durability and pricing. Even though the FQ3 core growth guide of 4.4%-5.9% and $1.83B-$1.85B revenue suggests modest progress, flat sequential EBIT, EPS of $1.48-$1.50, and only 80 bps of expected EBIT expansion leave limited room for margin upside, tariffs, phasing, and other execution risks.
This aggregate rating is based on analysts' research of Agilent Technologies and is not a guaranteed prediction by Public.com or investment advice.
Agilent Technologies (A) Analyst Forecast & Price Prediction
Start investing in Agilent Technologies (A)
Order type
Buy in
Order amount
Est. shares
0 shares